证券代码：603566 证券简称：普莱柯 公告编号：2025-049 普莱柯生物工程股份有限公司 关于拟认购中信农业所持中普生物股权暨购买资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、交易概述 中普生物由普莱柯、中牧实业股份有限公司（以下简称"中牧股份"）和中 信农业于 2018 年 6 月共同出资成立，经营范围主要为口蹄疫疫苗业务；截至目 前，普莱柯持股比例为 46.97%，中牧股份持股比例为 48.99%，中信农业持股比 例为 4.04%。 近日，中信农业将其持有的中普生物 4.04%股权在上海联合产权交易所挂牌 转让，转让标的对应评估值和转让底价为 1,751.43 万元。公司为改善中普生物经 营状况，根据长远发展需要，拟受让该部分股权。根据中普生物股东协议，经中 牧股份同意后，公司拥有对该部分股权的优先购买权。近日，公司收到中牧股份 函件，同意解除对公司购买该部分股权的限制。如有第三方摘牌，公司将视情况 决定是否行使优先购买权；如无第三方摘牌，公司将受让该部分股权，并获得中 交易内容概 ...

格隆汇12月2日丨普莱柯(603566.SH)公布，近日，中信农业将其持有的中普生物4.04%股权在上海联合 产权交易所挂牌转让，转让标的对应评估值和转让底价为1,751.43万元。公司为改善中普生物经营状 况，根据长远发展需要，拟受让该部分股权。根据中普生物股东协议，经中牧股份同意后，公司拥有对 该部分股权的优先购买权。近日，公司收到中牧股份函件，同意解除对公司购买该部分股权的限制。如 有第三方摘牌，公司将视情况决定是否行使优先购买权；如无第三方摘牌，公司将受让该部分股权，并 获得中普生物的控制权。 ...

智通财经APP讯，普莱柯(603566.SH)发布公告，公司拟认购中信农业科技股份有限公司(简称"中信农 业")持有的中普生物制药有限公司(简称"中普生物")股权。若本次交易能够完成，公司将获得中普生物 的控制权。 ...

普莱柯（603566）(603566.SH)发布公告，公司拟认购中信农业科技股份有限公司(简称"中信农业")持有 的中普生物制药有限公司(简称"中普生物")股权。若本次交易能够完成，公司将获得中普生物的控制 权。 ...

Core Viewpoint - The company, Pulaike, plans to acquire a 4.04% stake in Zhongpu Bio held by CITIC Agriculture, with the transfer valuation and minimum transfer price set at 17.5143 million yuan [1] Group 1: Transaction Details - CITIC Agriculture is transferring its 4.04% stake in Zhongpu Bio, which primarily focuses on foot-and-mouth disease vaccine business [1] - Pulaike, Zhongmu Co., and CITIC Agriculture hold 46.97%, 48.99%, and 4.04% stakes in Zhongpu Bio, respectively [1] - Pulaike has the right of first refusal for this stake acquisition [1] Group 2: Corporate Governance - The board of directors of Pulaike has approved the transaction on December 2, 2025, and it does not require shareholder approval [1] - The transaction does not constitute a related party transaction or a major asset restructuring [1] Group 3: Control Implications - If the transaction is completed, Pulaike will gain control over Zhongpu Bio [1]

Core Viewpoint - The animal health sector experienced a decline of 0.48% on December 1, with *ST Lvkang leading the drop, while the overall market indices showed positive performance with the Shanghai Composite Index rising by 0.65% and the Shenzhen Component Index increasing by 1.25% [1][2]. Market Performance - The closing price of *ST Lvkang was 39.35, reflecting a decrease of 3.41% with a trading volume of 30,400 shares and a transaction value of 122 million yuan [2]. - Other notable stocks in the animal health sector included: - Dayu Biological: Closing price 8.26, up 2.10% [1] - Haili Biological: Closing price 6.86, up 1.03% [1] - Qihua Biological: Closing price 15.85, up 0.51% [1] - Repu Biological: Closing price 19.83, down 0.10% [1][2]. Capital Flow - The animal health sector saw a net outflow of 29.57 million yuan from institutional investors, while retail investors contributed a net inflow of 3.27 million yuan [2][3]. - Specific stock capital flows included: - Jinhai Biological: Net inflow from institutional investors of 3.13 million yuan [3]. - Haili Biological: Net inflow from institutional investors of 2.06 million yuan [3]. - Repu Biological: Net inflow from retail investors of 2.81 million yuan [3].

Core Insights - The avian influenza concept sector experienced a decline of 0.76%, ranking among the top losers in the market, with major stocks like Zhongsheng Pharmaceutical hitting the limit down, while a few stocks like Wens Foodstuff and Weilan Biology saw gains of 1.80% each [1][2] Market Performance - The top-performing concept sectors included Titanium Dioxide with a gain of 4.31%, and Hainan Free Trade Zone with a gain of 3.54%, while the avian influenza sector was among the worst performers [1] - The avian influenza sector saw a net outflow of 784 million yuan, with 18 stocks experiencing net outflows, led by Zhongsheng Pharmaceutical with a net outflow of 684 million yuan [1] Stock Performance - Stocks with significant net outflows included: - Zhongsheng Pharmaceutical: -10.00% with a turnover rate of 18.78% and a net outflow of 683.65 million yuan - Yiling Pharmaceutical: -2.40% with a net outflow of 35.71 million yuan - Lianhuan Pharmaceutical: -1.79% with a net outflow of 25.69 million yuan - Hualan Biological: -6.60% with a net outflow of 18.13 million yuan [1] - Conversely, stocks with net inflows included: - Tiankang Biological: +1.26% with a net inflow of 16.52 million yuan - Shanghai Kaibao: -1.70% with a net inflow of 5.06 million yuan - Jinhai Biological: +0.16% with a net inflow of 3.82 million yuan [2]

北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2025 年第二次临时股东大会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话：010-52682888 传真：010-52682999 邮编：100033 北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2025 年第二次临时股东大会的法律意见 北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2025 年第二次临时股东大会的 法律意见 德恒 01G20250867-01 号 致： 普莱柯生物工程股份有限公司 北京德恒律师事务所受普莱柯生物工程股份有限公司（以下简称"普莱柯" 或"公司"）委托，指派黄丰、赖元超律师（以下简称"本所律师"）出席普莱 柯 2025 年第二次临时股东大会（以下简称"本次股东大会"），对本次股东大 会的合法性进行见证并出具法律意见。 本所及本所律师根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规 则（试行）》的规定及本法律意见出具日以前已经发生或者存在的事实，严格履 行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分 ...

证券代码：603566 证券简称：普莱柯 公告编号：2025-048 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 普莱柯生物工程股份有限公司 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 11 月 27 日 (二)股东大会召开的地点：河南省洛阳市洛龙区政和路 15 号公司二楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 117 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 119,766,328 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 35.0277 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由公司董事会召集，由董事长张许科先生主持，本次会议以现场投票与 网络投票相结合的方式召开，北京德恒律师事务所律师出席了现场会议 ...

Market Review - The agricultural, forestry, animal husbandry, and fishery sector has outperformed the benchmark index since the beginning of 2025, with an absolute return of +24.66%, surpassing the CSI 300 index by 10.47 percentage points [10][17][18] - The sector's index has increased by 18.4% over the past year, outperforming the CSI 300 index by 0.96 percentage points [14] Swine Breeding - The breeding capacity of sows is gradually declining, with a total of 39.9 million sows recorded by the end of October 2025, a year-on-year decrease of 2.04% [27][24] - The average price of live pigs in October 2025 was 11.52 yuan/kg, reflecting a month-on-month decline of 11.46% and a year-on-year drop of 34.77% [29] - The swine breeding industry is currently facing losses, with theoretical profits for self-bred pigs averaging -209.67 yuan/head in October 2025, marking a significant decline from previous months [36][41] - The market share of the top eight listed pig companies has increased from 4.6% in 2017 to 21.2% by the third quarter of 2025, indicating a trend towards industry consolidation [37][41] Animal Health - The animal health market in China has shown steady growth, with sales increasing from 47.23 billion yuan in 2016 to 69.65 billion yuan in 2023, reflecting a compound annual growth rate of 5.71% [45][46] - The introduction of new products and the expansion of demand are driving the growth of the animal health industry, particularly with the anticipated market expansion following the launch of African swine fever vaccines [51][52] - The market for companion animal health products is also growing, with the pet medical market expected to reach approximately 84 billion yuan in 2024, driven by increased spending on veterinary services [56] Seed Industry - The seed industry is experiencing a transformation due to new regulations and policies, with significant investment opportunities arising from the commercialization of biotechnology [4][19] - The market for genetically modified corn is projected to expand, with companies in the sector expected to benefit from increased industry concentration and profitability [18][19] Pet Food - China's pet food market is projected to continue growing, benefiting from demographic changes and rising living standards, with significant potential for domestic brands to capture market share [5][59] - The market for pet food exports is expected to maintain year-on-year growth in 2025, reflecting the increasing demand for high-quality pet products [5][59] - The pet food industry remains fragmented, with ongoing trends towards domestic substitution and increased online sales [5][59]